Publications
Wookey V, Hall M. Detecting molecular residual disease to inform CRC treatment: are we ready for universal postoperative ctDNA screening? ASCO Daily News. June 16, 2022.
Gile J, Wookey V, Zemla T, Hassan H, Shi Q, Borad M, Bekaii-Saab T, Tran N, Mahipal A. Outcomes following FGFR inhibitor therapy in patients with cholangiocarcinoma: Multi-center single institution cohort experience. Poster Presentation. European Society for Medical Oncology World Congress on Gastrointestinal Cancer Annual Meeting. Barcelona, Spain, June 2022.
Soderberg L, Wookey V, Mitchell J, Jochum J, Tran N, Halfdanarson T, Hubbard J, Graham R, Mathis K, Mahipal A, Jin Z. Clinical outcomes of neoadjuvant treatment strategies in localized mismatch repair-deficient rectal cancer. Poster Presentation. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, January 2022.
Wookey V, Mehler S, Stein M, Norton A, Grothey A, Somer B. “Impact of circulating tumor DNA (ctDNA) on clinical decisions in the adjuvant setting in patients with colorectal cancer (CRC)”. Poster Presentation. European Society for Medical Oncology World Congress on Gastrointestinal Cancer Annual Meeting [Virtual]. July 2021.
Wookey V, Schwartzberg L. Chapter 52: Hematologic support of the cancer patient; pp 766-784. In Principles and Practice of Palliative Care and Supportive Oncology, 5th edition: Wolters Kluwer; Philadelphia, PA; 2021. Ed: Berger AM, O’Neill JF.
Wookey V, Grothey A. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therap Adv Gastroenterol. June 2020; 14: 1-9.
Wookey V, Bufalino G, Vidal G, Somer B, Schwartzberg L, Grothey A. “Racial and Socioeconomic disparities in overall survival in colorectal cancer (CRC) at West Cancer Center (WCC), Memphis, TN”. Poster Presentation. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, January 2020.
Patient Comments